Polycomb Repressive Complex 2 and Atherosclerosis
Author Information
Author(s): Joshi Divyesh, Chakraborty Raja, Bhogale Tejas, Furtado Jessica, Deng Hanqiang, Traylor James G. Jr., Orr Anthony Wayne, Martin Kathleen A., Schwartz Martin A.
Primary Institution: Yale University
Hypothesis
Does Polycomb Repressive Complex 2 (PRC2) promote atherosclerotic plaque vulnerability by suppressing protective Klf2/4 transcription?
Conclusion
Inhibiting PRC2 with Tazemetostat significantly slows plaque progression and improves plaque stability in a mouse model of atherosclerosis.
Supporting Evidence
- PRC2 activity is elevated in human ASCVD endothelium.
- Tazemetostat treatment slowed plaque progression by 50%.
- Elevated PRC2 activity correlates with increased plaque vulnerability.
- Notch signaling is essential for Klf2/4 transcription.
- PRC2 inhibition improves markers of plaque stability.
Takeaway
This study found that a protein complex called PRC2 makes plaques in blood vessels more dangerous, but a drug can help make them safer.
Methodology
The study used a combination of genome-wide CRISPR-Cas9 screening, ChIP-seq, and pharmacological inhibition in mouse models to assess the role of PRC2 in atherosclerosis.
Potential Biases
Potential bias may arise from the specific focus on PRC2 without considering other regulatory pathways in atherosclerosis.
Limitations
The study's findings may not fully translate to human conditions due to the limitations of using hyperlipidemic mice as models.
Participant Demographics
The study included de-identified human samples from elderly donors and patients with atherosclerotic cardiovascular disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website